Autor(es): Ferreira, Débora ; Cátia S. Pereira ; Costa, Marta ; Afonso, Julieta ; Longatto, Adhemar ; Baltazar, Fátima ; Kalluri, Raghu ; Moreira, João N. ; Rodrigues, L. R.
Data: 2022
Identificador Persistente: https://hdl.handle.net/1822/76240
Origem: RepositóriUM - Universidade do Minho
[Excerpt] Introduction: Breast cancer is a major public health problem worldwide being the most diagnosed cancer in women [1] . Triple negative breast cancer (TNBC) represents 10-20% of all breast cancers and is characterized by the absence of hormone receptors (progesterone and estrogen) and lack of expression of epidermal growth factor receptor 2. Furthermore, it is also described to have poor prognosis due to its propensity to metastasize to visceral organs early in the clinical course [2–4] . In accordance with the lack of recurrently altered targets at the genomic level, there is a shortage of approved targeted agents for TNBC, remaining cytotoxic chemotherapy the mainstay of treatment. [...]
